Malignant News and Research

RSS

UT Southwestern researchers identify cell signaling mechanism that plays vital role in brain cancer

UT Southwestern Medical Center neurology researchers have identified an important cell signaling mechanism that plays an important role in brain cancer and may provide a new therapeutic target.

16 Dec 2014

Research finding could lead to new therapies for malignant glioma

Targeted therapies are a growing and groundbreaking field in cancer care in which drugs or other substances are designed to interfere with genes or molecules that control the growth and survival of cancer cells. Now, scientists at Virginia Commonwealth University Massey Cancer Center and VCU Institute of Molecular Medicine (VIMM) have identified a novel interaction between a microRNA and a gene that could lead to new therapies for the most common and deadly form of brain tumor, malignant glioma.

12 Dec 2014

Genetic variations may contribute to treatment-related cognitive problems in children with ALL

Common variations in four genes related to brain inflammation or cells' response to damage from oxidation may contribute to the problems with memory, learning and other cognitive functions seen in children treated for acute lymphoblastic leukemia (ALL), according to a study led by researchers from Boston Children's Hospital, The Children's Hospital at Montefiore, and Dana-Farber/Boston Children's Cancer and Blood Disorders Center.

10 Dec 2014

Heat-shock protein 90 enables ER+ breast cancers to develop resistance to hormonal therapy

Long known for its ability to help organisms successfully adapt to environmentally stressful conditions, the highly conserved molecular chaperone heat-shock protein 90 (HSP90) also enables estrogen receptor-positive (ER+) breast cancers to develop resistance to hormonal therapy.

10 Dec 2014

Epizyme presents EPZ-5676 Phase 1 trial results for acute leukemia at ASH 2014

Epizyme, Inc., a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today the presentation of results from the company’s Phase 1 trial of EPZ-5676, a potent and selective inhibitor of the DOT1L histone methyltransferase (HMT).

10 Dec 2014

Study finds that disarray in methylation helps tumors adapt to changing circumstances

The genetic tumult within cancerous tumors is more than matched by the disorder in one of the mechanisms for switching cells' genes on and off, scientists at Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard report in a new study.

9 Dec 2014

Agent THZ1 shrinks human-like small cell lung tumors in mice

Small cell lung cancer - a disease for which no new drugs have been approved for many years - has shown itself vulnerable to an agent that disables part of tumor cells' basic survival machinery, researchers at Dana-Farber Cancer Institute and the Massachusetts Institute of Technology reported.

9 Dec 2014

BAZ2A protein directly influences the aggressiveness of prostate cancer

A protein that influences the epigenetic characteristics of tumor cells is directly linked to the grade of malignancy of prostate cancer. This key discovery has been made by a team of scientists from the German Cancer Research Center, the University of Zurich, Hamburg-Eppendorf University Hospital, Heidelberg University, and other institutes in a study of 7,700 samples of tumor tissue.

9 Dec 2014

PRM-151 compound shows positive results for treating advanced myelofibrosis

A study that investigated the potential of the compound PRM-151 (PRM) for reducing progressive bone marrow fibrosis (scarring) in patients with advanced myelofibrosis has shown initial positive results. Myelofibrosis is a life-threatening bone marrow cancer.

8 Dec 2014

Amgen's XGEVA (denosumab) receives FDA approval for treatment of hypercalcemia of malignancy

Amgen today announced that the U.S. Food and Drug Administration has approved a new indication for XGEVA (denosumab) for the treatment of hypercalcemia of malignancy (HCM) refractory to bisphosphonate therapy.

8 Dec 2014

Researchers identify new targets for future CLL therapies

Chronic lymphocytic leukemia (CLL) is among the most frequent leukemias affecting adults in Western countries. It usually occurs in older patients, does not cause any symptoms for a long time and is often only discovered by accident. Despite treatment, relapses frequently occur. The immunologists Dr. Kristina Heinig and Dr. Uta Höpken (Max Delbrück Center for Molecular Medicine, MDC, Berlin-Buch) and the hematologist Dr. Armin Rehm (MDC and Charité - Universitätsmedizin Berlin) have now discovered why this is so.

7 Dec 2014

Nivolumab drug highly effective for Hodgkin's lymphoma

A phase I clinical trial of nivolumab found that the immune-boosting drug is a highly effective therapy for Hodgkin's lymphoma. The multi-institution study, led by Mayo Clinic, indicated that the drug was safe and led to an 87 percent response rate in patients who had failed on other treatments.

7 Dec 2014

New treatment combinations improve outcomes for vulnerable patient with hard-to-treat disease

New treatment combinations and targeted therapies for lymphoma and multiple myeloma are improving outcomes for vulnerable patient populations with hard-to-treat disease, according to studies presented today at the 56th American Society of Hematology Annual Meeting and Exposition.

7 Dec 2014

IMBRUVICA demonstrates anti-tumor activity against multiple myeloma in Phase II study

New IMBRUVICA (ibrutinib) Phase II data announced here today by Pharmacyclics, Inc) during the 56th American Society of Hematology Annual Meeting suggests that IMBRUVICA demonstrates anti-tumor activity both as a single-agent and as combination therapy in heavily pre-treated patients with relapsed or relapsed/refractory multiple myeloma (MM).

7 Dec 2014

Novel treatments show safe responses in patients with relapsed, treatment-resistant blood cancers

Novel treatments that harness the body's own immune cells to attack cancer cells demonstrate safe and durable responses in patients with relapsed and treatment-resistant blood cancers, according to data presented today at the 56th American Society of Hematology Annual Meeting and Exposition.

7 Dec 2014

Scientists suspect role of mini-chromosomes in cancers, diseases caused by gene mutations

Cancers are due to genetic aberrations in certain cells that gain the ability to divide indefinitely. This proliferation of sick cells generates tumors, which gradually invade healthy tissue. Therefore, current therapies essentially seek to destroy cancer cells to stop their proliferation. Through high-throughput genetic sequencing of glioblastoma cells, one of the most deadly brain tumors, a team of geneticists from the University of Geneva's (UNIGE) Faculty of Medicine discovered that some of these mutations are caused by supplemental extrachromosomal DNA fragments, called double minutes, which enable cancer cells to better adapt to their environment and therefore better resist to treatments meant to destroy them.

6 Dec 2014

Malnutrition predicts long-term survival in elderly patients undergoing Whipple procedure

Malnutrition is an important factor predicting long-term survival in older patients undergoing pancreaticoduodenectomy (PD) (commonly called the Whipple procedure) to treat benign tumors and cysts of the pancreas as well as pancreatitis, according to new study results published in the December issue of the Journal of the American College of Surgeons.

6 Dec 2014

Pharmacyclics wins 2014 Society for Medicines Research Award for Drug Discovery

Pharmacyclics, Inc. today announced that it has won the prestigious 2014 Society for Medicines Research Award for Drug Discovery for its discovery of ibrutinib (IMBRUVICA). The award was presented by The Society of Medicines Research at its biennial award lecture in Kensington, London.

4 Dec 2014

Protein that regulates the body's sleep cycle may offer cancer protection

People who work around the clock could actually be setting themselves back, according to Virginia Tech biologists.

4 Dec 2014

Faster and more accurate method for testing new cancer drugs

Finding faster and more accurate ways to test new cancer drugs is always a priority for cancer researchers.

2 Dec 2014

Malignant News and Research

UT Southwestern researchers identify cell signaling mechanism that plays vital role in brain cancer

Research finding could lead to new therapies for malignant glioma

Genetic variations may contribute to treatment-related cognitive problems in children with ALL

Heat-shock protein 90 enables ER+ breast cancers to develop resistance to hormonal therapy

Epizyme presents EPZ-5676 Phase 1 trial results for acute leukemia at ASH 2014

Study finds that disarray in methylation helps tumors adapt to changing circumstances

Agent THZ1 shrinks human-like small cell lung tumors in mice

BAZ2A protein directly influences the aggressiveness of prostate cancer

PRM-151 compound shows positive results for treating advanced myelofibrosis

Amgen's XGEVA (denosumab) receives FDA approval for treatment of hypercalcemia of malignancy

Researchers identify new targets for future CLL therapies

Nivolumab drug highly effective for Hodgkin's lymphoma

New treatment combinations improve outcomes for vulnerable patient with hard-to-treat disease

IMBRUVICA demonstrates anti-tumor activity against multiple myeloma in Phase II study

Novel treatments show safe responses in patients with relapsed, treatment-resistant blood cancers

Scientists suspect role of mini-chromosomes in cancers, diseases caused by gene mutations

Malnutrition predicts long-term survival in elderly patients undergoing Whipple procedure

Pharmacyclics wins 2014 Society for Medicines Research Award for Drug Discovery

Protein that regulates the body's sleep cycle may offer cancer protection

Faster and more accurate method for testing new cancer drugs

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News